IPO nears for Durham firm: Bioventus prices its stock, targets $104M raise
Bioventus, the Durham-based life science company focusing on a variety of treatments targeting bones and joint pain, is another step closer to going public.
Read More
bioventus
Triangle life science firm Bioventus gears up for IPO, looking to raise $125M or more
Life sciences firm Bioventus is gearing up to launch its IPO this week, looking to raise as much as $125 million.
Read More
Try – and try again for IPO: Life science firm Bioventus aims for $100M offering
Biotech companies continue to jump in line to join the public markets. Bioventus, a medical device maker whose portfolio includes biological products that promote bone healing, is now adding its name to the mix.
Read More
Durham-based Bioventus invests $15M in Israeli firm, has option to buy it
Bioventus, a global orthobiologics company headquartered in Durham, could become the owner of an Israeli company if that firm secures FDA approval for an implant it has under development.
Read More
Durham firm touts new bone graft substitute as offering boost to healing
Durham-based Bioventus has come up with a new bone graft substitute that it says is easier for doctors to handle, promotes healing in patients, and provides potential cost savings for hospitals.
Read More
Durham orthobiologic firm Bioventus CEO to retire; successor is industry vet
Bioventus, a orthobiologic company focused on osteoarthritis, surgical and non-surgical bone healing, is getting a new chief executive officer.
Read More
Placental tissue injections from Durham firm Bioventus could bring knee pain relief
Durham-based global orthobiologic company Bioventus and nonprofit Edison, NJ-based MTF Biologics, the largest tissue bank in the world, are betting that placental tissue from the birth of newborns can inject new life into the aching knees of older adults suffering from osteoarthritis.
Read More
Bioventus expands its bone graft substitutes product line
Durham-based Bioventus, which develops orthobiologic products, is launching OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of bone graft substitutes for spine, foot and ankle, orthopaedic, and trauma surgeons.
Read More
Durham-based Bioventus to sell tech it had acquired from Pfizer
Bioventus, a global orthobiologics company based in Durham, is selling a bone morphogenetic protein program to a New York firm that plans to form a new venture around the technology.
Read More
